United Therapeutics Wins Patent Case Against Liquidia’s Yutrepia
A Delaware judge found Liquidia’s Yutrepia infringes United Therapeutics’ PH-ILD patent. Final judgment is next.
/ 3 items
#LQDA↓
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
United Therapeutics Unveils Tresmi: The "Category Killer" Inhaler Set to End Coughing Woes in PAH and ILD
United Therapeutics announces Tresmi, a revolutionary soft mist inhaler version of Treprostinil that cuts coughing side effects by up to 90%. Planned approval filing this year and launch next year, impacting strategic partner MannKind's stock.